Research output per year
Research output per year
Fingerprint
Dive into the research topics where Maida Zivalj is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Infection history imprints prolonged changes to the epigenome, transcriptome and function of Kupffer cells
Musrati, M. A., Stijlemans, B., Azouz, A., Kancheva, D., Mesbahi, S., Hadadi, E., Lebegge, E., Ali, L., Vlaminck, K. D., Scheyltjens, I., Vandamme, N., Zivalj, M., Assaf, N., Elkrim, Y., Ahmidi, I., Huart, C., Lamkanfi, M., Guilliams, M., Baetselier, P. D., Goriely, S. & 2 others, , Dec 2024, In: Journal of Hepatology. 81, 6, p. 1023-1039 17 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
A few good reasons to use nanobodies for cancer treatment: A few good reasons to use nanobodies for cancer treatment
Jumapili, N. A., Zivalj, M., Barthelmess, R. M., Raes, G., De Groof, T. W. M., Devoogdt, N., Stijlemans, B., Vincke, C. & Van Ginderachter, J. A., Sep 2023, In: European Journal of Immunology. 53, 9, p. 1-8 8 p., e2250024.Research output: Contribution to journal › Article › peer-review
Open AccessFile9 Citations (Scopus)38 Downloads (Pure) -
Flt3L therapy increases the abundance of Treg-promoting CCR7+ cDCs in preclinical cancer models
Clappaert, E., Kancheva, D., Debraekeleer, A., Brughmans, J., Bardet, P., Elkrim, Y., Lacroix, D., Zivalj, M., Hamouda, A. E. I., Van Ginderachter, J., Deschoemaeker, S. & Laoui, D., 16 Oct 2023.Research output: Unpublished contribution to conference › Poster
-
Targeting Lcn-2 as a novel strategy to disrupt the iron-trafficking mechanism within the tumor microenvironment
Gupta, M. S., Zivalj, M., Stijlemans, B. & Van Ginderachter, J., 2023, (Unpublished). 1 p.Research output: Unpublished contribution to conference › Poster
-
Lipocalin-2 (Lcn-2) as a potential target in triple negative breast carcinoma
Zivalj, M., Van Ginderachter, J., Stijlemans, B. & Vincke, C., 18 Oct 2022.Research output: Unpublished contribution to conference › Poster
-
Flt3L therapy increases the abundance of Treg-promoting CCR7+ cDCs in preclinical cancer models
Emile Clappaert (Speaker), Daliya Kancheva (Contributor), Jan Brughmans (Contributor), Ayla Debraekeleer (Contributor), Pauline Bardet (Contributor), Yvon Elkrim (Contributor), Dagmar Lacroix (Contributor), Maida Zivalj (Contributor), Ahmed Emad Ibrahim Hamouda (Contributor), Jo Van Ginderachter (Contributor), Sofie Deschoemaeker (Contributor) & Damya Laoui (Contributor)
16 Oct 2023Activity: Talk or presentation › Talk or presentation at a conference
-
Flt3L therapy induces a Treg-promoting cDC1 state in triple-negative breast cancer
Emile Clappaert (Speaker), Daliya Kancheva (Contributor), Jan Brughmans (Contributor), Ayla Debraekeleer (Contributor), Pauline Bardet (Contributor), Yvon Elkrim (Contributor), Dagmar Lacroix (Contributor), Maida Zivalj (Contributor), Ahmed Emad Ibrahim Hamouda (Contributor), Jo Van Ginderachter (Contributor), Sofie Deschoemaeker (Contributor) & Damya Laoui (Contributor)
8 Jun 2023Activity: Talk or presentation › Talk or presentation at a workshop/seminar
Thesis
-
Validation of anti-Lipocalin-2 Nanobodies (anti-Lcn-2 Nbs) as anti-tumor treatment
Author: Živalj, M., Van Ginderachter, J., Raes, G. & Stijlemans, B., 4 Sep 2020Student thesis: Master's Thesis